-
Improvement in Liver Fibrosis with Semaglutide
Semaglutide
Novo Nordisk announces promising Phase III results from the ESSENCE study of semaglutide, showing significant improvement in liver fibrosis for patients with metabolic dysfunction-associated fatty liver disease (MAFLD). With plans for regulatory approval applications in 2025.
-
-
-
-
昂仁县|
兰西县|
留坝县|
梓潼县|
双流县|
温州市|
两当县|
定南县|
通渭县|
浮梁县|
扶风县|
扬州市|
大理市|
和林格尔县|
灌云县|
南木林县|
临泉县|
师宗县|
涟水县|
宾阳县|
顺义区|
龙泉市|
阳东县|
岚皋县|
涞源县|
莲花县|
许昌市|
罗平县|
西乡县|
博客|
丹东市|
瑞昌市|
长垣县|
普格县|
景谷|
巴林右旗|
张家港市|
微山县|
成武县|
安乡县|
汕头市|